Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights into the durability of immune and clinical responses up to three years Extension...Read more
Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent steroids Potential trend to improved grip strength observed, with average...Read more
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the...Read more
Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects. Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by...Read more
GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that...Read more
PRINCETON, N.J. / May 21, 2025 / Business Wire / UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced the outcome of today’s meeting of the Oncologic Drugs Advisory...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Acadia Pharmaceuticals | 4.23 24.08 | $21.80 |
| Adaptive Biotechnologies | 1.89 26.96 | $8.91 |
| Ascendis Pharma | 1.39 0.88 | $159.49 |
| Abeona Therapeutics | 0.66 11.54 | $6.38 |
| ABVC BioPharma | 0.62 106.47 | $1.20 |
| Achieve Life Sciences | 0.25 8.72 | $3.06 |
| Alector | 0.11 8.40 | $1.36 |
| Alterity Therapeutics | 0.10 2.49 | $4.11 |
| Atara Biotherapeutics | 0.09 1.30 | $6.99 |
| Arvinas | 0.08 1.28 | $6.34 |
| Aurinia Pharmaceuticals | 0.07 0.84 | $8.41 |
| Aldeyra Therapeutics | 0.07 2.93 | $2.32 |
| Akero Therapeutics | 0.06 0.12 | $48.42 |
| BioCryst Pharmaceuticals | 0.06 0.60 | $10.13 |
| Aprea Therapeutics | 0.06 3.69 | $1.66 |
| Alzamend Neuro | 0.05 1.39 | $3.57 |
| Adaptimmune Therapeutics | 0.04 18.39 | $0.28 |
| Atai Life Sciences | 0.04 2.15 | $1.95 |
| Company | Volume | Last Trade |
|---|---|---|
| Aptevo Therapeutics | 2,169,399 | $0.30 |
| Alector | 707,415 | $1.36 |
| Onconetix | 689,716 | $0.08 |
| Applied Therapeutics | 300,018 | $0.39 |
| Atai Life Sciences | 271,872 | $1.95 |
| Autolus Therapeutics | 249,160 | $1.50 |
| Akero Therapeutics | 240,306 | $48.42 |
| Absci | 217,029 | $2.65 |
| AbCellera Biologics | 209,645 | $1.95 |
| Ardelyx | 178,451 | $3.95 |
| Akebia Therapeutics | 156,020 | $2.83 |
| Arvinas | 155,825 | $6.34 |
| Candel Therapeutics | 122,370 | $5.44 |
| Cabaletta Bio | 119,954 | $1.74 |
| Aurinia Pharmaceuticals | 111,413 | $8.41 |
| BioCryst Pharmaceuticals | 109,778 | $10.13 |
| BioMarin Pharmaceutical | 108,314 | $58.07 |
| Annexon | 103,736 | $2.00 |
| Brainstorm Cell Therapeutics | 99,823 | $1.08 |
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
